1. Home
  2. ATOS vs AXTI Comparison

ATOS vs AXTI Comparison

Compare ATOS & AXTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATOS
  • AXTI
  • Stock Information
  • Founded
  • ATOS 2009
  • AXTI 1986
  • Country
  • ATOS United States
  • AXTI United States
  • Employees
  • ATOS N/A
  • AXTI N/A
  • Industry
  • ATOS Biotechnology: Pharmaceutical Preparations
  • AXTI Semiconductors
  • Sector
  • ATOS Health Care
  • AXTI Technology
  • Exchange
  • ATOS Nasdaq
  • AXTI Nasdaq
  • Market Cap
  • ATOS 174.8M
  • AXTI 146.1M
  • IPO Year
  • ATOS 2012
  • AXTI 1998
  • Fundamental
  • Price
  • ATOS $1.47
  • AXTI $2.53
  • Analyst Decision
  • ATOS Strong Buy
  • AXTI Strong Buy
  • Analyst Count
  • ATOS 3
  • AXTI 4
  • Target Price
  • ATOS $6.25
  • AXTI $5.38
  • AVG Volume (30 Days)
  • ATOS 575.2K
  • AXTI 279.7K
  • Earning Date
  • ATOS 11-12-2024
  • AXTI 10-31-2024
  • Dividend Yield
  • ATOS N/A
  • AXTI N/A
  • EPS Growth
  • ATOS N/A
  • AXTI N/A
  • EPS
  • ATOS N/A
  • AXTI N/A
  • Revenue
  • ATOS N/A
  • AXTI $88,406,000.00
  • Revenue This Year
  • ATOS N/A
  • AXTI $40.18
  • Revenue Next Year
  • ATOS N/A
  • AXTI $21.52
  • P/E Ratio
  • ATOS N/A
  • AXTI N/A
  • Revenue Growth
  • ATOS N/A
  • AXTI N/A
  • 52 Week Low
  • ATOS $0.62
  • AXTI $1.89
  • 52 Week High
  • ATOS $2.31
  • AXTI $5.64
  • Technical
  • Relative Strength Index (RSI)
  • ATOS 54.46
  • AXTI 54.91
  • Support Level
  • ATOS $1.40
  • AXTI $2.28
  • Resistance Level
  • ATOS $1.58
  • AXTI $2.58
  • Average True Range (ATR)
  • ATOS 0.08
  • AXTI 0.17
  • MACD
  • ATOS -0.00
  • AXTI 0.06
  • Stochastic Oscillator
  • ATOS 52.17
  • AXTI 75.71

About ATOS Atossa Therapeutics Inc.

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

About AXTI AXT Inc

AXT Inc is a developer and producer of compound and single-element semiconductor substrates, also known as wafers. The dominant substrates used in producing semiconductor chips and other electronic circuits are made from silicon. It is engaged in the design, development, manufacture, and distribution of high-performance compound semiconductor substrates and the sale of materials. The company provides alternative or specialty materials in the form of substrates or wafers, including compound and single-element substrates. Its compound substrates combine indium with phosphorous or gallium with arsenic. Geographically firm has its business presence across the region of Europe, Japan, Taiwan, China, North America, and the Asia Pacific from which China derives its maximum revenue to the company.

Share on Social Networks: